A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C-C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. A randomized, double-blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fatty l...

Full description

Bibliographic Details
Main Authors: Friedman, Scott L., Ratziu, Vlad, Harrison, Stephen A., Abdelmalek, Manal F., Aithal, Guruprasad P., Caballeria, Juan, Francque, Sven, Farrell, Geoffrey, Kowdley, Kris V., Craxi, Antonio, Simon, Krzysztof, Fischer, Laurent, Melchor-Khan, Liza, Vest, Jeffrey, Wiens, Brian L., Vig, Pamela, Seyedkazemi, Star, Goodman, Zachary, Wong, Vincent Wai-Sun, Loomba, Rohit, Tacke, Frank, Sanyal, Arun, Lefebvre, Eric
Format: Article
Language:English
Published: Wiley 2018
Subjects:
NASH
NAFLD
CVC
nonalcoholic fatty liver
inflammation
Online Access:https://eprints.nottingham.ac.uk/45019/

Similar Items

Similar Items